These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 10605760

  • 1. Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in postmenopausal women.
    Koh KK, Horne MK, Cannon RO.
    Thromb Haemost; 1999 Aug; 82(2):626-33. PubMed ID: 10605760
    [No Abstract] [Full Text] [Related]

  • 2. Controversies regarding hormone therapy: Insights from inflammation and hemostasis.
    Koh KK, Yoon BK.
    Cardiovasc Res; 2006 Apr 01; 70(1):22-30. PubMed ID: 16412400
    [Abstract] [Full Text] [Related]

  • 3. Effects of hormone replacement therapy on blood coagulation and fibrinolysis in hypertensive and normotensive postmenopausal women.
    Sumino H, Ichikawa S, Sawada Y, Sakamoto H, Kumakura H, Takayama Y, Sakamaki T, Kurabayashi M.
    Thromb Res; 2005 Apr 01; 115(5):359-66. PubMed ID: 15733968
    [Abstract] [Full Text] [Related]

  • 4. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
    Dias AR, Melo RN, Gebara OC, D'Amico EA, Nussbacher A, Halbe HW, Pinotti JA.
    Climacteric; 2005 Mar 01; 8(1):63-70. PubMed ID: 15804733
    [Abstract] [Full Text] [Related]

  • 5. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature.
    Cosman F, Baz-Hecht M, Cushman M, Vardy MD, Cruz JD, Nieves JW, Zion M, Lindsay R.
    Thromb Res; 2005 Mar 01; 116(1):1-13. PubMed ID: 15850603
    [Abstract] [Full Text] [Related]

  • 6. Coagulation and fibrynolitic parameters in women and the effects of hormone therapy; comparison of transdermal and oral administration.
    Połać I, Borowiecka M, Wilamowska A, Nowak P.
    Gynecol Endocrinol; 2013 Feb 01; 29(2):165-8. PubMed ID: 23116237
    [Abstract] [Full Text] [Related]

  • 7. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
    Vehkavaara S, Silveira A, Hakala-Ala-Pietilä T, Virkamäki A, Hovatta O, Hamsten A, Taskinen MR, Yki-Järvinen H.
    Thromb Haemost; 2001 Apr 01; 85(4):619-25. PubMed ID: 11341495
    [Abstract] [Full Text] [Related]

  • 8. Coagulation, oestrogen and the menopause.
    Notelovitz M.
    Clin Obstet Gynaecol; 1977 Apr 01; 4(1):107-28. PubMed ID: 140032
    [Abstract] [Full Text] [Related]

  • 9. Does estrogen replacement therapy predispose to thrombosis?
    Astedt B.
    Acta Obstet Gynecol Scand Suppl; 1985 Apr 01; 130():71-4. PubMed ID: 3859978
    [No Abstract] [Full Text] [Related]

  • 10. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
    Keramaris NC, Christodoulakos GE, Lambrinoudaki IV, Dalamanga A, Alexandrou AP, Bramis J, Bastounis E, Creatsas GC.
    Climacteric; 2007 Oct 01; 10(5):400-7. PubMed ID: 17852143
    [Abstract] [Full Text] [Related]

  • 11. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B, Guzic-Salobir B, Sebestjen M, Keber I.
    Menopause; 2006 Oct 01; 13(4):643-50. PubMed ID: 16837886
    [Abstract] [Full Text] [Related]

  • 12. Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial.
    Hemelaar M, Kenemans P, Hack CE, Klipping C, van der Mooren MJ.
    Menopause; 2008 Oct 01; 15(2):248-55. PubMed ID: 17693902
    [Abstract] [Full Text] [Related]

  • 13. The menopause and hormone replacement therapy: lipids, lipoproteins, coagulation and fibrinolytic factors.
    Tikkanen MJ.
    Maturitas; 1996 Mar 01; 23(2):209-16. PubMed ID: 8735358
    [Abstract] [Full Text] [Related]

  • 14. Exercise, nutrition, and the coagulation effects of estrogen replacement on cardiovascular health.
    Notelovitz M.
    Obstet Gynecol Clin North Am; 1987 Mar 01; 14(1):121-41. PubMed ID: 3306516
    [Abstract] [Full Text] [Related]

  • 15. Assessment of DNA damage in postmenopausal women under hormone replacement therapy.
    Ozcagli E, Sardas S, Biri A.
    Maturitas; 2005 Jul 16; 51(3):280-5. PubMed ID: 15978971
    [Abstract] [Full Text] [Related]

  • 16. Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis.
    Eilertsen AL, Sandvik L, Mowinckel MC, Andersen TO, Qvigstad E, Sandset PM.
    Thromb Res; 2007 Jul 16; 120(3):371-9. PubMed ID: 17156824
    [Abstract] [Full Text] [Related]

  • 17. Coagulation and fibrinolysis in estrogen-treated surgically menopausal women.
    Notelovitz M, Kitchens CS, Ware MD.
    Obstet Gynecol; 1984 May 16; 63(5):621-5. PubMed ID: 6326012
    [Abstract] [Full Text] [Related]

  • 18. [Atherosclerosis].
    Akishita M, Ouchi Y.
    Nihon Rinsho; 2006 Apr 16; 64 Suppl 4():381-6. PubMed ID: 16689338
    [No Abstract] [Full Text] [Related]

  • 19. Mechanisms of hormonal therapy related thrombosis.
    Sandset PM.
    Thromb Res; 2013 Jan 16; 131 Suppl 1():S4-7. PubMed ID: 23452740
    [Abstract] [Full Text] [Related]

  • 20. [Hormone replacement therapy and cardiovascular risk in postmenopausal women].
    Kovacev-Zavisić B, Icin T, Kovacev N.
    Med Pregl; 2009 Jan 16; 62 Suppl 3():85-90. PubMed ID: 19702123
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.